Clinical Trial Outcomes for Cardiac Myosin Inhibitors in oHCM Treatment
An expert in cardiology shares clinical trial findings of emerging and approved cardiac myosin inhibitors for the treatment of oHCM.
Source: hcplive.com
Valor Hcm News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Valor Hcm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Valor Hcm Today - Breaking & Trending Today
Dr Milind Desai on VALOR-HCM: Primary and Secondary Effects Are Sustained While on Mavacamten
Secondary effects not only improved past 16 weeks, but showed a sustained improvement at week 56 of mavacamten, said Milind Desai, MD, MBA, director of the Hypertrophic Cardiomyopathy Center and vice chair of education at the Heart, Vascular & Thoracic Institute, Cleveland Clinic.
Source: ajmc.com
Dr Milind Desai Highlights New Findings From VALOR-HCM Trial
After 16 weeks on placebo, patients in the control group were invited to start mavacamten alongside the treatment group, explained Milind Desai, MD, MBA, director of the Hypertrophic Cardiomyopathy Center and vice chair of education at the Heart, Vascular & Thoracic Institute, Cleveland Clinic.
Source: ajmc.com